Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: the case study of Japan.
CONCLUSIONS: Introducing rivaroxaban may decrease the burden of NVAF in Japanese society. From a clinical perspective, the reduction in IS and embolic events outweighs the increased risk of anticoagulant-related bleeding; from an economic perspective, reduced event costs offset drug and physician visit costs, resulting in cost savings.
PMID: 27112188 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Aspirin | Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Economics | Health | Health Management | Heart | Ischemic Stroke | Japan Health | Stroke | Study | Vitamins